SynthesisTumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine2014
Lack of association between MTHFD1 G401A polymorphism and ovarian cancer susceptibility.
Synthesis in Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Common Variants in One-Carbon Metabolism Genes (International journal of molecular sciences · 2023Article
- Folate Pathway Gene Single Nucleotide Polymorphisms and Neural Tube Defects: A Systematic Review and Meta-Analysis.Journal of personalized medicine · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Published studies on the association between methylenetetrahydrofolate dehydrogenase 1 (MTHFD1) G401A polymorphism and ovarian cancer risk have yielded conflicting results. In order to derive a more precise estimation of the relationship between G401A polymorphism and ovarian cancer risk, the present meta-analysis was performed. All eligible studies on G401A polymorphism and ovarian cancer risk were collected from the PubMed and the Cochrane Library. Statistical analyses were performed by Review Manage 5.0 and Stata 11.0. Our analysis suggested that G401A polymorphism was not associated with ovarian cancer risk when using additive (odds ratio (OR) = 1.72, 95% confidence interval (CI) = 1.34-2.20, P < 0.0001), recessive (OR = 1.46, 95% CI = 1.21-1.77, P < 0.0001), dominant (OR = 1.36, 95% CI = 1.10-1.69, P = 0.004), and allelic models (OR = 1.30, 95% CI = 1.15-1.47, P < 0.0001) to analyze the data. This meta-analysis suggests that G401A polymorphism might not be a risk factor for ovarian cancer risk. However, further well-designed studies are required to confirm our findings.
Indexed as
Identifiers
24287951What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.